KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
2021 · The Lancet · 721 citations
https://doi.org/10.1016/s0140-6736(21)01222-8
A
Aaron C. Logan
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
385
Papers
6.7K
Citations
39
h-index
83
i10-index
Aaron C. Logan is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Acute Lymphoblastic Leukemia research & CAR-T cell therapy research & Acute Myeloid Leukemia Research. The author has an h-index of 39, co-authored 328 publications.
ORCID: 0000-0002-1179-5879Papers by this author
worksA Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk
2018 · Diabetes Care · 165 citations
https://doi.org/10.2337/dc18-0087
Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia
2024 · New England Journal of Medicine · 145 citations
https://doi.org/10.1056/nejmoa2406526
Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation
2020 · Antimicrobial Agents and Chemotherapy · 32 citations
https://doi.org/10.1128/aac.02467-19
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL
2024 · Journal of Clinical Oncology · 25 citations
https://doi.org/10.1200/jco.24.00321
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
2025 · Leukemia · 22 citations
https://doi.org/10.1038/s41375-025-02532-7
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat